BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: Proof of principle

European Journal of Haematology

Volumn 91, Issue 6, 2013, Pages 552-556

  Chevallier, Patrice ^a   Bodet Milin, Caroline ^b   Robillard, Nelly ^b   Eugene, Thomas ^b   Menard, Audrey ^b   Le Houerou, Claire ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Escoffre Barbe, Martine ^c   Wegener, William A ^d   Goldenberg, David M ^d   Kraeber Bodéré, Francoise ^b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d IMMUNOMEDICS INC   (United States)

Author keywords

B acute lymphoblastic leukemia; BCR ABL1; CD22; Epratuzumab; Radioimmunotherapy; Relapse; Yttrium

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; CD22 ANTIGEN; DASATINIB; EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IMATINIB; PONATINIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; B ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW BIOPSY; CASE REPORT; CYTOPENIA; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETREATMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

B-ACUTE LYMPHOBLASTIC LEUKEMIA; BCR-ABL1; CD22; EPRATUZUMAB; RADIOIMMUNOTHERAPY; RELAPSE; YTTRIUM;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE MARROW; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASM, RESIDUAL; PHENOTYPE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; SIALIC ACID BINDING IG-LIKE LECTIN 2; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84888057303     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12183     Document Type: Article

References (15)

1. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy 2011;3:349-70.
2. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 2002;9:106-13.
3. Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012;26:25-32.
4. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol 2008;26:3756-62.
5. Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foá R, Guarini A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leukemia & Lymphoma 2011;52:1098-107.
6. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34.
7. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011;118:4053-61.
8. Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. Blood 2012;12: Abstract 2603.
9. 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11:5215-22.
10. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:3709-16.
11. 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a LYSA Phase II prospective trial. Blood 2012;120: Abstract 906.
12. De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:1408-13.
13. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau MS, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997;11:2039-44.
14. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study Group. Haematologica 2010;95:589-96.
15. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982S-90S.